Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-2


Brief Information

Target Synonym:ANGPT2,Angiopoietin 2,ANG-2,Angiopoietin-2B,Angiopoietin-2a,Angiopoietin-2,Tie2-Ligand,AGPT2,ANG2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 Angiopoietin-2 SPR

Rabbit Angiopoietin-2 Protein, His Tag (Cat. No. AN2-R52H4) captured on CM5 chip via anti-His antibody can bind Human TIE2, Fc Tag (Cat. No. TI2-H5255) with an affinity constant of 43.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

 Angiopoietin-2 ELISA

Immobilized Mouse Angiopoietin-2, His Tag (Cat. No. AN2-M5245) at 2 μg/mL (100 μL/well) can bind Human TIE2, Fc Tag (Cat. No. TI2-H5255) with a linear range of 0.039-0.625 μg/mL (QC tested).

Synonym Name



Angiopoietin-2 is also known as ANGPT2, AGPT2, ANG2, and is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Ang2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel Palade bodies. Both Ang2 and the related Angiopoietin1 (Ang1) are ligands for the receptor tyrosine kinase Tie 2. Ang2 functions as a proangiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang2 is required for postnatal vascular remodeling, and it cooperates with Ang1 during lymphatic vessel development. It mediates the upregulation of ICAM1 and VCAM1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang2 competitively inhibit Ang1-induced endothelial cell responses mediated by Tie2, and reduces vascular integrity. But the role of Ang2 is controversial since the opposite outcomes has been reported in other studies. Over-expression of Ang2 disrupts the vascular remodeling, induce endothelial cell apoptosis, and may play an important regulating role in tumor angiogenesis. Ang2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Faricimab RG-7716; RO-6867461 Approved F. Hoffmann-La Roche Ltd, Genentech Inc Vabysmo EU Wet Macular Degeneration; Diabetes Complications; Macular Edema Roche Registration Gmbh 2022-01-28 Macular Edema; Choroid Diseases; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy; Diabetes Mellitus; Retinal Vein Occlusion; Macular Degeneration; Choroidal Neovascularization Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RG-6120 RG-6120 Phase 1 Clinical F. Hoffmann-La Roche Ltd Macular Degeneration Details
RO-7250284 RO-7250284 F. Hoffmann-La Roche Ltd Details
MEDI-3617 ANG-2-mAb; MEDI-3617; Anti-ANG-2-mAb Medimmune Details
PF-5057459 CVX-241; CovX-241; PF-05057459 Pfizer Pharmaceuticals Ltd (China) Details
Zansecimab LY-3127804 Eli Lilly And Company Details
IBI-324 IBI-324 Phase 1 Clinical Innovent Biologics (Usa), Inc Diabetic macular oedema Details
ASKG-712 AM-712; ASKG-712 Phase 1 Clinical Wet Macular Degeneration; Macular Degeneration Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code) Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms; Colorectal Neoplasms Details
Trebananib AMG-386; 20060439 Phase 2 Clinical Amgen Inc, Takeda Pharmaceutical Co Ltd Fallopian Tube Neoplasms; Breast Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Sarcoma; Peritoneal Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Gliosarcoma; Endometrial Neoplasms; Carcinoma, Adenosquamous; Lung Neoplasms; Uterine Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Monocytic, Acute; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Neoplasms; Solid tumours; Leukemia, Myeloid; Leukemia, Erythroblastic, Acute; Carcinoma; Carcinoma, Renal Cell; Rectal Neoplasms; Hemangiosarcoma; Colonic Neoplasms; Ovarian Neoplasms; Kidney Diseases; Leukemia, Myelomonocytic, Acute; Glioblastoma; Sarcoma, Endometrial Stromal; Central Nervous System Neoplasms; Neuroendocrine Tumors; Leukemia, Megakaryoblastic, Acute; Oligodendroglioma Details
BI-836880 BI-836880 Phase 2 Clinical Ablynx Nv Neoplasms; Wet Macular Degeneration Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message